Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus.

Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus.
复制标题

DOI:
10.1016/j.virol.2014.02.005
复制
发表时间:
2014-04
期刊:
影响因子:
3.7
通讯作者:
Kai C
Kai C
中科院分区:
医学3区
文献类型:
--
作者:
Yasui F;Kohara M;Kitabatake M;Nishiwaki T;Fujii H;Tateno C;Yoneda M;Morita K;Matsushima K;Koyasu S;Kai C

文献摘要

参考文献

被引文献

相似文献

虽然2002-2003年爆发的严重急性呼吸系统综合征(SARS)导致774人死亡,但患有轻微肺部症状的患者成功康复。本工作的目的是确定,使用SARS冠状病毒(SARS-CoV)的小鼠感染模型,负责清除病毒的免疫因子。肺SARS-CoV感染的消除需要CD 4 + T细胞激活B细胞。此外,被动免疫(感染后)与同源(鼠)抗SARS冠状病毒抗血清显示更大的消除效果对SARS冠状病毒比异源(兔)抗血清,尽管使用等效滴度的中和抗体。这种区别是由小鼠吞噬细胞(单核细胞来源的浸润性巨噬细胞和部分肺泡巨噬细胞,但不是中性粒细胞)介导的,如通过供体过继转移和所选细胞类型的免疫耗竭所证明的。这些结果表明,抗SARS-CoV抗体和吞噬细胞的协同作用在SARS-CoV的清除中起重要作用。
While the 2002–2003 outbreak of severe acute respiratory syndrome (SARS) resulted in 774 deaths, patients who were affected with mild pulmonary symptoms successfully recovered. The objective of the present work was to identify, using SARS coronavirus (SARS-CoV) mouse infection models, immune factors responsible for clearing of the virus. The elimination of pulmonary SARS-CoV infection required the activation of B cells by CD4+ T cells. Furthermore, passive immunization (post-infection) with homologous (murine) anti-SARS-CoV antiserum showed greater elimination efficacy against SARS-CoV than that with heterologous (rabbit) antiserum, despite the use of equivalent titers of neutralizing antibodies. This distinction was mediated by mouse phagocytic cells (monocyte-derived infiltrating macrophages and partially alveolar macrophages, but not neutrophils), as demonstrated both by adoptive transfer from donors and by immunological depletion of selected cell types. These results indicate that the cooperation of anti-SARS-CoV antibodies and phagocytic cells plays an important role in the elimination of SARS-CoV.
DOI: 10.1001/jama.290.3.367
发表时间: 2003-07-16
影响因子: 120.7
作者:
Fowler, RA;Lapinsky, SE;Stewart, TE
通讯作者: Stewart, TE
通过马中和 F(ab')2 保护中国仓鼠模型免受严重急性呼吸综合征冠状病毒感染。
DOI: 10.1089/vim.2007.0038
发表时间: 2007-09-01
期刊: VIRAL IMMUNOLOGY
影响因子: 2.2
作者:
Luo, Deyan;Ni, Bing;Wang, Xiliang
通讯作者: Wang, Xiliang
DOI: 10.1016/s0046-8177(03)00367-8
发表时间: 2003-08
期刊: Human pathology
影响因子: 3.3
作者:
Franks TJ;Chong PY;Chui P;Galvin JR;Lourens RM;Reid AH;Selbs E;McEvoy CP;Hayden CD;Fukuoka J;Taubenberger JK;Travis WD
通讯作者: Travis WD
DOI: 10.1084/jem.20052246
发表时间: 2006-12-25
影响因子: 15.3
作者:
Casazza, Joseph P.;Betts, Michael R.;Price, David A.;Precopio, Melissa L.;Ruff, Laura E.;Brenchley, Jason M.;Hill, Brenna J.;Roederer, Mario;Douek, Daniel C.;Koup, Richard A.
通讯作者: Koup, Richard A.
DOI: 10.1016/s0140-6736(03)13413-7
发表时间: 2003-05-24
期刊: Lancet (London, England)
影响因子: --
作者:
Nicholls JM;Poon LL;Lee KC;Ng WF;Lai ST;Leung CY;Chu CM;Hui PK;Mak KL;Lim W;Yan KW;Chan KH;Tsang NC;Guan Y;Yuen KY;Peiris JS
通讯作者: Peiris JS